nm32-2668
Leiomyosarcoma
Numab Therapeutics AGPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
17 Active assets in the Leiomyosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib National Cancer Institute (NCI) | Phase 2 | B |
Temsirolimus National Cancer Institute (NCI) | Phase 2 | B |
Cixutumumab National Cancer Institute (NCI) | Phase 2 | B |
vx-970 Massachusetts General Hospital | Phase 2 | B |
Cediranib University Health Network, Toronto | Phase 2 | CCC |
View all 26 →
Same molecule, other indications
nm32-2668 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →